edf40wrjww2CF_PaperMaster:Desc
Summary to advanced technologies. The Company's major research focus lays in Urology, Anti-infectives, Respiratory, Anti-inflammatory and Metabolic disorders segments. Ranbaxy’s vision is to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets.1 The Story Established in 1961, Ranbaxy Laboratories is India’s largest pharmaceutical and ranks 9th worldwide as a generics drug manufacturer.2 The company went public in 1973 and began the first of its several strategic alliances through a joint venture in Nigeria in 1977. The Ranbaxy research foundation was initiated in 1985 and several more production facilities were in place by 1987. Its plant in Toansa, Punjab, which is the largest manufacturer of antibiotics, got US FDA approval in After being granted a few US patents for its drugs, Ranbaxy entered a joint venture with US pharmaceutical giant, Eli Lilly & Co. to market certain Lilly products in the Indian market. The company forayed into the Chinese market through the Guangzhou China joint venture in 1993. Ohm Laboratories, a manufacturing facility in the US was acquired in 1995 and its state-of the art manufacturing wing was FDA approved to run as Ranbaxy’s US subsidiary Ohm Laboratories Inc. 1998 was a milestone as Ranbaxy entered the US, the largest pharmaceutical market and distributed products under its own brand name. Ranbaxy enters into Brazil, the largest pharmaceutical market in South America and achieves global sales of US $2.5 million in this market by 2000 and acquired Bayer AG’s generics business ...